73 related articles for article (PubMed ID: 10198979)
1. [Quality criteria for cost-benefit analysis in oncologic nuclear medicine and state of its realization].
Dietlein M; Scheidhauer K; Lauterbach KW; Schicha H
Z Arztl Fortbild Qualitatssich; 1999 Jan; 93(1):49-55. PubMed ID: 10198979
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of PET imaging in clinical oncology.
Valk PE; Pounds TR; Tesar RD; Hopkins DM; Haseman MK
Nucl Med Biol; 1996 Aug; 23(6):737-43. PubMed ID: 8940715
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation studies in nuclear medicine: the need for standardization.
Dietlein M; Knapp WH; Lauterbach KW; Schicha H
Eur J Nucl Med; 1999 Jun; 26(6):663-80. PubMed ID: 10369954
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
J Nucl Med Technol; 2010 Mar; 38(1):6-17. PubMed ID: 20197541
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
Buck AK; Herrmann K; Stargardt T; Dechow T; Krause BJ; Schreyögg J
J Nucl Med; 2010 Mar; 51(3):401-12. PubMed ID: 20150250
[TBL] [Abstract][Full Text] [Related]
6. Value of 99m-Tc MIBI and 99m-Tc(V) DMSA scintigraphy in evaluation of breast mass lesions.
Ambrus E; Rajtár M; Ormándi K; Séra T; Tószegi A; Láng J; Pávics L; Csernay L
Anticancer Res; 1997; 17(3B):1599-605. PubMed ID: 9179201
[TBL] [Abstract][Full Text] [Related]
7. The current status of positron emission tomography.
Digby W; Keppler J
Radiol Manage; 2000; 22(1):37-40. PubMed ID: 10787760
[TBL] [Abstract][Full Text] [Related]
8. An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography.
Miles KA
Australas Radiol; 2001 Feb; 45(1):9-18. PubMed ID: 11259966
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of positron emission tomography/computed tomography in the management of advanced head and neck cancer.
Kurien G; Hu J; Harris J; Seikaly H
J Otolaryngol Head Neck Surg; 2011 Dec; 40(6):468-72. PubMed ID: 22420434
[TBL] [Abstract][Full Text] [Related]
11. Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism.
Wang TS; Cheung K; Farrokhyar F; Roman SA; Sosa JA
Surgery; 2011 Dec; 150(6):1286-94. PubMed ID: 22136852
[TBL] [Abstract][Full Text] [Related]
12. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
13. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
14. Decision analysis: MIBI imaging of nonpalpable breast abnormalities.
Hillner BE
J Nucl Med; 1997 Nov; 38(11):1772-8. PubMed ID: 9374352
[TBL] [Abstract][Full Text] [Related]
15. In an era of tough choices, what is your comfort level?
DePuey EG
J Nucl Med; 1993 Oct; 34(10):1829-31. PubMed ID: 8280253
[No Abstract] [Full Text] [Related]
16. Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion.
Leitha T; Glaser C; Pruckmayer M; Rasse M; Millesi W; Lang S; Nasel C; Backfrieder W; Kainberger F
J Nucl Med; 1998 Jul; 39(7):1166-71. PubMed ID: 9669388
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation studies in nuclear medicine: a methodological review of the literature.
Gambhir SS; Schwimmer J
Q J Nucl Med; 2000 Jun; 44(2):121-37. PubMed ID: 10967623
[TBL] [Abstract][Full Text] [Related]
18. Tough choices: who is to make the call?
Kalus ME
J Nucl Med; 1993 May; 34(5):860-1. PubMed ID: 8478725
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness in nuclear medicine.
Patton DD
Semin Nucl Med; 1993 Jan; 23(1):9-30. PubMed ID: 8469998
[TBL] [Abstract][Full Text] [Related]
20. Interpreting the economic literature in oncology.
Grusenmeyer PA; Wong YN
J Clin Oncol; 2007 Jan; 25(2):196-202. PubMed ID: 17210940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
